BIOSENSORS FOR MEASURING ANALYTES IN THE INTERSTITIAL FLUID

• US 20080275318A1
• Filed: 04/21/2008
• Published: 11/06/2008
• Est. Priority Date: 04/20/2007
• Status: Abandoned Application

• Current Assignee: Becton, Dickinson & Co
• Original Assignee: Becton, Dickinson & Co
• Inventors: Alarcon, Javier, Vonk, Glenn, LASTOVICH, Alexander, Hartsell, Jacob, Roberts, Bruce Clyde
• Application Number:
  US12/107,033
• Publication Number:
  US 20080275318A1
• Time in Patent Office: Days
• US Class Current: 600/316
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/1455 using optical sensors, e.g. spectral photometrical oximeters
• CPC Class Codes: A61B 5/411 Detecting or monitoring allergy or intolerance reactions to an allergenic agent or substance

Abstract

The invention relates to methods and devices for measuring blood glucose levels in a subject, where the methods and devices are designed for exposing a sensing mechanism to interstitial fluid in the subject.

Claims

1. A method for determining the blood levels of glucose in a subject, the method comprising

a) inserting in the skin of the subject to a depth of up to about 2 mm from the surface of the skin, a sensor that produces a detectable signal in the presence of glucose in the interstitial fluid of the subject,

b) maintaining said sensor in the skin at said depth such that at least a portion of said sensor is exposed to the interstitial fluid in the skin,

c) measuring the detectable signal of the sensor produced by said sensor upon exposure to said interstitial fluid, and

d) correlating the signal produced by the sensor to the level of blood glucose, thereby determining the levels of blood glucose in the subject.

2. The method of claim 1, wherein the sensor comprises a glucose-galactose binding protein (GGBP).

3. The method of claim 2, wherein the GGBP is labeled with a signaling moiety that emits an optical signal.

4. The method of claim 1, wherein a needle houses the sensor, said needle comprising a body with a proximal end and a distal end, wherein the proximal end of the needle comprises a tip, said needle being a 31 gauge needle or smaller.

5. The method of claim 1, wherein the sensor is inserted into the subject at a depth of between about 0.1 mm and 2 mm below the surface the skin.

6. The method of claim 5, wherein the sensor is inserted into the subject at a depth of between about 0.1 mm and 1 mm below the surface the skin.

7. The method of claim 6, wherein the sensor is inserted into the subject at a depth of between about 0.1 mm and 0.8 mm below the surface the skin.

8. The method of claim 1, wherein the sensor remains inserted in the subject for at least one day.

9. The method of claim 1, wherein the sensor is a continuous sensor.

10. The method of claim 1, wherein the sensor produces an optical signal in the presence of glucose for at least 4 hours.

11. The method of claim 1, wherein the subject is under a physiological stress that results in decreased peripheral blood flow.

12. A biosensor for detecting blood glucose levels in a subject, the biosensor comprising

a) a sensing mechanism that produces an optical signal in the presence of glucose said sensing mechanism comprising a fluorescently labeled glucose-galactose binding protein (GGBP) entrapped within a hydrogel matrix,

b) a shallow-depth housing that encases the sensing mechanism, wherein the shallow-depth housing comprises a hollow needle, wherein said hollow needle is a 31 gauge needle or smaller and penetrates the skin of a subject to a depth of up to about 2 mm from the surface of the skin such that said sensing mechanism is exposed to interstitial fluid, and

c) an optical conduit, wherein said optical conduit is in optical connectivity with said sensing mechanism and the needle houses at least a portion of said conduit

wherein the optical signal of the sensing mechanism generated from exposure to the interstitial fluid of the subject is correlated to blood glucose levels.

13. The biosensor of claim 12, wherein the sensing mechanism provides continuous sensing of glucose levels.

14. The biosensor of claim 13, wherein the sensor produces an optical signal in the presence of glucose for at least 4 hours.

15. The biosensor of claim 12 wherein the fluorescently labeled GGBP is covalently bound to the hydrogel matrix.

16. The biosensor of claim 15, wherein the hydrogel matrix comprises poly(ethylene glycol) dimethylacrylate (PEGDMA), 2-hydroxy-2 methyl propiophenone (HMPP) and at least one acrylate, wherein the acrylate is selected from the group consisting of methacrylic acid (MAA) and methyl methacrylate (MMA).